Haemonetics Co. (NYSE:HAE) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Haemonetics Co. (NYSE:HAE) by 41.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,258 shares of the medical instruments supplier’s stock after buying an additional 3,274 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Haemonetics were worth $931,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. TFO Wealth Partners LLC raised its position in shares of Haemonetics by 29,450.0% during the fourth quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 589 shares during the period. Covestor Ltd raised its holdings in Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 438 shares during the period. EntryPoint Capital LLC purchased a new stake in Haemonetics during the first quarter valued at about $86,000. Headlands Technologies LLC acquired a new position in shares of Haemonetics in the first quarter worth about $114,000. Finally, Central Pacific Bank Trust Division purchased a new position in shares of Haemonetics in the first quarter worth approximately $139,000. Institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

HAE has been the subject of a number of recent analyst reports. Needham & Company LLC raised shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a research note on Wednesday, June 12th. Barrington Research lifted their price target on Haemonetics from $107.00 to $108.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Citigroup reduced their price objective on Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, August 22nd. Finally, JMP Securities reiterated a “market outperform” rating and issued a $125.00 target price on shares of Haemonetics in a report on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $107.50.

Haemonetics Price Performance

HAE opened at $75.07 on Wednesday. The company has a current ratio of 3.76, a quick ratio of 2.33 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 1 year low of $70.74 and a 1 year high of $97.97. The stock has a fifty day moving average price of $82.91 and a 200 day moving average price of $84.00. The stock has a market cap of $3.83 billion, a price-to-earnings ratio of 32.78, a PEG ratio of 1.38 and a beta of 0.29.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing the consensus estimate of $1.03 by ($0.01). The firm had revenue of $336.17 million during the quarter, compared to the consensus estimate of $335.08 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The company’s quarterly revenue was up 8.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.05 EPS. Analysts forecast that Haemonetics Co. will post 4.58 EPS for the current fiscal year.

Insider Transactions at Haemonetics

In related news, EVP Anila Lingamneni sold 2,136 shares of the company’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $90.00, for a total value of $192,240.00. Following the completion of the sale, the executive vice president now directly owns 21,410 shares in the company, valued at $1,926,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Anila Lingamneni sold 2,136 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total value of $192,240.00. Following the completion of the sale, the executive vice president now directly owns 21,410 shares in the company, valued at approximately $1,926,900. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Stewart W. Strong sold 4,312 shares of the company’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $91.15, for a total value of $393,038.80. Following the sale, the insider now directly owns 18,196 shares of the company’s stock, valued at approximately $1,658,565.40. The disclosure for this sale can be found here. 1.80% of the stock is currently owned by company insiders.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.